Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Xconomy Texas Austin — A year after releasing results from a Phase 2 clinical trial, Savara Pharmaceuticals has announced $20 million in Series C funding that it will use to take its inhaled version of an antibiotic to Phase 3.

Continue reading Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Teva announces FDA approval of generic TOBI in the United States

JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States